头像

Jia Chen, PhDProfessor

Tel:

Email: chenjia@@shanghaitech.edu.cn

Fax: 86-21-20685430

Add: 393 Middle Huaxia Road, Pudong, Shanghai

Faculty KMS Profile

中文信息English
Group of DNA Repair, Gene Editing & Gene Therapy

Principal investigator

Name:

Jia ChenProfessor , PhD, Professor

Position:

Director of Gene Editing Center

Affiliation:

School of Life Science and Technology

Honor:

Education Background:
  • 1998/09-2002/06, College of Life Science, Nankai University, BS
  • 2002/09-2009/04, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, PhD
Working Experience:
  • 2009/07-2014/06, National Institutes of Health, Postdoc Fellow
  • 2014/11-2019/09, School of Life Science and Technology, ShanghaiTech University, Assistant Professor (Tenure-Track)
  • 2019/10-2024/01, School of Life Science and Technology, ShanghaiTech University, Associate Professor (Tenured)
  • 2024/02-Now, School of Life Science and Technology, ShanghaiTech University, Professor (Tenured)

Group Introduction

Research Area:
DNA Repair, Gene Editing and Gene Therapy
Research Interests:

Species survival is closely related to genome stability, which is monitored and maintained by DNA repair pathways. However, cells can initiate error-prone DNA repair under various physiological and pathological conditions. Thus, the fidelity of DNA repair influences aging, evolution, and certain diseases.

Genome editing is a type of genetic engineering in which DNA is inserted, deleted, or replaced in the genome of a living organism using engineered nucleases. Utilizing genome editing tools to genetically manipulate the genome of cells and living organisms has broad applications in life sciences research, biotechnology and agricultural technology development, and, most importantly, pharmaceutical and clinical innovation.

Our lab focuses on DNA repair-induced mutagenesis, the development and application of new gene editing systems, and gene editing therapy. We are particularly interested in: (1) DNA repair-induced mutagenesis in gene editing, carcinogenesis, and aging; (2) the development of new gene editing tools; and (3) gene editing therapy for human diseases.


Group Website:
http://jchenlab.org/

Research Achievement

Our lab revealed the molecular mechanism by which the cytidine deaminase APOBEC induces mutations during CRISPR/Cas9-mediated gene editing has been elucidated. Building on this mechanistic study, multiple novel base editing systems have been developed, including: an enhanced Cas9 base editor (eBE) with high efficiency; a Cpf1 base editor (dCpf1-BE) capable of effective editing in genomic A/T-rich regions; a universal Cas9 base editor (hA3A-BE) demonstrating high efficiency in G/C-rich and hypermethylated regions; a Cas12a base editor (BEACON) with minimal activation of DNA damage response pathways; an enhanced mitochondrial adenine base editor (eTALED); and a high-precision RNA adenine base editor (RtABE).

To address off-target risks in clinical applications, a high-precision base editor (transformer BE, tBE) was developed using cytidine deaminase inhibitory proteins. Employing tBE, we achieved the world's first clinical application of base editing for β-thalassemia treatment. To date, this approach has successfully treated patients with β-hemoglobinopathies across multiple countries (including China, Laos, Malaysia, Nigeria and Pakistan). The related drug candidate CS-101 received IND approval for Phase I clinical trials from China's National Medical Products Administration (NMPA) in 2024. Recognized as a groundbreaking advancement in β-hemoglobinopathy treatment, it was featured in the European Hematology Association Congress (EHA2024) Scientific Report.

Representative Publications (*First Author, # Corresponding Author)

Monograph

Patent

Funding

Awards

Research Achievement

Group Member and Photo




返回原图
/